Sofinnova Partners
Investor profile
Investment firmVenture capital
Sofinnova Partners has backed 79 European tech companies across 117 funding rounds between 2004 and 2026, joining rounds totalling €3.0B. Most active in Healthtech and Software. Data as of Nov 2026.
Also recorded as: SOFINNOVA PARTNERS · Sofinnova Partners.
Deals
117
distinct rounds
Companies
79
backed
Active span
2004–2026
23 yrs
Total round €
€3.0B
sum of rounds joined
Deals by year
distinct rounds / yearSofinnova Partners — deals by year — interactive chart.
Data table
| Sofinnova Partners — deals by year | |
|---|---|
| 2004 | 1 |
| 2005 | 6 |
| 2006 | 9 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 2 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 9 |
| 2023 | 11 |
| 2024 | 8 |
| 2025 | 11 |
| 2026 | 7 |
Top sectors
by dealsSofinnova Partners — top sectors — interactive chart.
Data table
| Sofinnova Partners — top sectors | |
|---|---|
| Healthtech | 71 |
| Software | 11 |
| Agritech | 9 |
| Cybersecurity | 6 |
| AI | 4 |
| Semiconductors | 4 |
| Marketing | 3 |
| Cleantech | 3 |
| Gaming | 3 |
| Deeptech | 2 |
Stages
by dealsSofinnova Partners — stages — interactive chart.
Data table
| Sofinnova Partners — stages | |
|---|---|
| Other | 33 |
| Series A | 33 |
| Series B | 17 |
| Series C | 15 |
| Seed | 8 |
| Early VC | 4 |
| Series D+ | 4 |
| Growth/Late | 3 |
Countries
by dealsSofinnova Partners — countries — interactive chart.
Data table
| Sofinnova Partners — countries | |
|---|---|
| France | 62 |
| UK | 14 |
| Switzerland | 13 |
| Netherlands | 6 |
| Germany | 5 |
| Denmark | 4 |
| Italy | 4 |
| Sweden | 3 |
| Belgium | 2 |
| Finland | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- Bpifrance9
- GIMV6
- Novo Holdings6
- Forbion5
- Invus5
- Roche Venture Fund5
- Supernova Invest5
- Andera Partners4
- Seventure Partners4
- Cathay Health3
- EQT Life Sciences3
- European Circular Bioeconomy Fund (ECBF)3
- Gilde Healthcare3
- Groupe Siparex3
- IDInvest Partners3
- IRDInov3
- Kurma Partners3
- Novo Seeds3
- Sacha Loiseau3
- Schroders Capital3
- XAnge3
- 5AM Ventures2
- Almi Invest Greentech2
- Amadeus Capital Partners2
- Asabys Partners2
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Artios | UK | 2 | €229M |
| GlycoEra | Switzerland | 2 | €157M |
| Noema Pharma | Switzerland | 2 | €134M |
| Amolyt Pharma | France | 1 | €129M |
| IOmx Therapeutics | Germany | 2 | €105M |
| Tissium | France | 2 | €100M |
| HighLife | France | 2 | €92M |
| SafeHeal | France | 4 | €91M |
| NanoPhoria | Italy | 1 | €84M |
| Moon Surgical | France | 2 | €81M |
| ObsEva | Switzerland | 2 | €80M |
| Merus | Netherlands | 1 | €73M |
| Bioptimus | France | 2 | €72M |
| Northsea Therapeutics | Netherlands | 1 | €71M |
| Inside Secure | France | 4 | €69M |
| F2G | UK | 1 | €69M |
| Neurent Medical | Ireland | 1 | €63M |
| Elicit Plant | France | 2 | €62M |
| haya therapeutics | Switzerland | 1 | €58M |
| Latent Labs | UK | 1 | €48M |
| Ascendis Pharma | Denmark | 1 | €48M |
| Microphyt | France | 2 | €44M |
| Breath Therapeutics | Germany | 1 | €44M |
| Aledia | France | 2 | €40M |
| Mironid | UK | 1 | €40M |
| Micropep | France | 3 | €40M |
| Auris Medical | Switzerland | 1 | €40M |
| Synthace | UK | 2 | €39M |
| MISSION Therapeutics | UK | 2 | €35M |
| Sphere Fluidics | UK | 1 | €34M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Artios | Series C | €130M | 2021-07 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| GlycoEra | Series B | €114M | 2025-05 |
| Noema Pharma | Series B | €105M | 2023-03 |
| Artios | Series D+ | €99M | 2025-11 |
| NanoPhoria | Series A | €84M | 2025-10 |
| Merus | Series C | €73M | 2015-08 |
| Northsea Therapeutics | Other | €71M | 2021-12 |
| F2G | Other | €69M | 2022-08 |
| IOmx Therapeutics | Series B | €65M | 2021-10 |